Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial

Open access
Pérez-Larraya, Jaime Gállego, Ducray, François, Chinot, Olivier, Catry-Thomas, Isabelle, Taillandier, Luc, Guillamo, Jean-Sébastien, Campello, Chantal, Monjour, Annick, Cartalat-Carel, Stéphanie, Barrie, Maryline, Huchet, Aymeri, Beauchesne, Patrick, Matta, Mona, Mokhtari, Karima, Tanguy, Marie-Laure, Honnorat, Jérôme, Delattre, Jean-Yves·2011·Journal of Clinical Oncology

Abstract

Purpose: The management of glioblastoma multiforme (GBM) in elderly patients with poor performance status is not well established. A trial evaluating the efficacy and safety of temozolomide alone in this population was undertaken. Patients and Methods: Patients age 70 years or older with newly diagnosed GBM and postoperative Karnofsky performance score (KPS) less than 70 were eligible for this nonrandomized phase II trial. Treatment consisted of 150 to 200 mg/m 2 /d temozolomide for 5 days every 4 weeks until disease progression. Radiotherapy was not administered. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), safety, quality of life, and cognition. Results: Seventy patients (median age, 77 years; median KPS, 60) were enrolled between July 2007 and February 2009. Grade 3 to 4 neutropenia and thrombocytopenia occurred in 13% and 14% of patients, respectively. Median PFS was 16 weeks (95% CI, 10 to 20 weeks), and median OS was 25 weeks (95% CI, 19 to 28 weeks), comparing favorably with a 12- to 16-week OS expected from a purely supportive approach. Twenty-three patients (33%) improved their KPS by 10 or more points, and 18 (26%) became capable of self-care (KPS ≥ 70). Overall quality of life and cognition improved over time before disease progression. In the 31 tumors evaluated for O 6 -methylguanine–DNA methyltransferase (MGMT) promoter methylation, a methylated status indicated longer PFS (26 v 11 weeks; P = .03) and OS (31 v 19 weeks; P = .03). Conclusion: Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70. It is associated with improvement of functional status in 33% of patients and appears to increase survival compared with supportive care alone, especially in patients with methylated MGMT promoter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.34.8086

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 212

Metadata

Authors
Pérez-Larraya, J. G., Ducray, F., Chinot, O., Catry-Thomas, I., Taillandier, L., Guillamo, J.-S., Campello, C., Monjour, A., Cartalat-Carel, S., Barrie, M., Huchet, A., Beauchesne, P., Matta, M., Mokhtari, K., Tanguy, M.-L., Honnorat, J., & Delattre, J.-Y.
Venue
Journal of Clinical Oncology
Published
2011-08-01
Volume
29
Issue
22
Pages
3050-3055
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2135396269
Cited by
212
References
1
FWCI
10.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.2011.34.8086
The paper
Pérez-Larraya, J. G., Ducray, F., Chinot, O., Catry-Thomas, I., Taillandier, L., Guillamo, J.-S., Campello, C., Monjour, A., Cartalat-Carel, S., Barrie, M., Huchet, A., Beauchesne, P., Matta, M., Mokhtari, K., Tanguy, M.-L., Honnorat, J., & Delattre, J.-Y. (2011). Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.34.8086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.